For this article:

15 Feb 2026·Source: The Hindu
3 min
Science & TechnologySocial IssuesNEWS

Nitric Oxide: A Potential Treatment for Drug-Resistant Pneumonia?

High-dose inhaled nitric oxide reduces drug-resistant bacteria in ICU model; safety questions remain.

Researchers report that high-dose inhaled nitric oxide reduced drug-resistant Pseudomonas aeruginosa in a large-animal ICU model. A phase 1 study showed the treatment could be administered without immediate serious complications. However, questions remain about the method’s benefits and feasibility. Most hospitals are not equipped to deliver nitric oxide at high concentrations, and the process requires specialized machinery and trained staff.

Key Facts

1.

Drug-resistant pneumonia is a serious complication in intensive care units.

2.

Pseudomonas aeruginosa causes about one in five hospital pneumonias and often resists multiple drugs.

3.

High-dose inhaled nitric oxide reduced drug-resistant Pseudomonas in a large-animal ICU model.

4.

A phase 1 study showed the treatment could be administered without immediate serious complications in humans.

UPSC Exam Angles

1.

GS Paper III: Science and Technology - Developments and their applications and effects in everyday life

2.

Focus on drug resistance and potential solutions

3.

Statement-based MCQs on the properties and applications of nitric oxide

In Simple Words

Some pneumonia germs don't respond to regular medicines anymore. Scientists are checking if a gas used in hospitals, nitric oxide, can help fight these tough infections. They found that high doses of this gas can reduce the number of these germs in the lungs.

India Angle

In India, where antibiotic resistance is a growing problem, new ways to treat infections are crucial. This research could offer hope for patients in Indian hospitals struggling with drug-resistant pneumonia.

For Instance

Imagine your house has a stubborn cockroach problem, and the usual sprays don't work. This nitric oxide research is like finding a new, stronger spray that can finally get rid of those cockroaches.

Drug-resistant infections are becoming more common and harder to treat. This research could lead to new treatments that save lives and reduce the burden on our healthcare system.

Nitric oxide: a potential new weapon against drug-resistant pneumonia.

Visual Insights

Key Statistics from Nitric Oxide Pneumonia Treatment Study

Highlights from the research on inhaled nitric oxide for drug-resistant pneumonia.

Drug-Resistant Bacteria Targeted
Pseudomonas aeruginosa

This bacterium is a major cause of drug-resistant pneumonia, posing a significant threat to public health.

Treatment Method
High-dose inhaled nitric oxide

The study explored the effectiveness of high-dose inhaled nitric oxide in reducing drug-resistant bacteria.

More Information

Background

Nitric oxide (NO) is a molecule naturally produced by the human body and plays a crucial role in various physiological processes. It acts as a vasodilator, relaxing blood vessels and improving blood flow. This property has led to its use in treating conditions like pulmonary hypertension in newborns. The discovery of NO's biological significance earned Robert Furchgott, Louis Ignarro, and Ferid Murad the Nobel Prize in Physiology or Medicine in 1998. Beyond its role in vasodilation, nitric oxide also functions as a neurotransmitter and is involved in immune regulation. It is produced by various cells, including endothelial cells, neurons, and immune cells. The enzyme nitric oxide synthase (NOS) catalyzes the production of NO from L-arginine. There are three main isoforms of NOS: neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS), each with distinct functions and regulation. The therapeutic use of inhaled nitric oxide (iNO) has expanded over the years. Initially used for pulmonary hypertension in newborns, it is now being explored for other respiratory conditions, including acute respiratory distress syndrome (ARDS) and pneumonia. The effectiveness of iNO depends on factors such as the dose, duration of treatment, and the underlying condition. However, the high cost and logistical challenges associated with iNO delivery have limited its widespread adoption. The current research explores its potential against drug-resistant bacteria, a growing concern in healthcare.

Latest Developments

The rise of antimicrobial resistance (AMR) is a significant global health threat. Bacteria like Pseudomonas aeruginosa are becoming increasingly resistant to commonly used antibiotics, making infections harder to treat. This has led to a renewed interest in alternative therapies, including the use of nitric oxide. Researchers are exploring different methods of delivering nitric oxide, including inhaled formulations and topical applications. The goal is to maximize its therapeutic effects while minimizing potential side effects. Clinical trials are underway to evaluate the efficacy of nitric oxide in treating various infections, including those caused by drug-resistant bacteria. The development of new delivery systems and formulations could make nitric oxide more accessible and effective. Despite the promising results, challenges remain in translating research findings into clinical practice. Most hospitals lack the infrastructure and expertise to administer high-dose inhaled nitric oxide. Further research is needed to optimize treatment protocols and identify patients who are most likely to benefit from this therapy. The long-term effects of high-dose nitric oxide treatment also need to be carefully evaluated. The World Health Organization (WHO) is actively monitoring the AMR crisis and promoting research into new treatment strategies.

Frequently Asked Questions

1. What is the significance of Nitric Oxide (NO) in the context of drug-resistant pneumonia?

Nitric oxide, naturally produced by the body, acts as a vasodilator, improving blood flow. Research suggests that high-dose inhaled nitric oxide may reduce drug-resistant bacteria like Pseudomonas aeruginosa in intensive care units, offering a potential alternative treatment when antibiotics fail.

2. What concentration of nitric oxide is being tested for antimicrobial activity, and how does it compare to typical doses?

Researchers are testing a 300 ppm concentration of nitric oxide for its antimicrobial effects. This is significantly higher than the typical dose of 20-80 ppm, which is usually used to widen blood vessels.

3. What are the potential challenges in implementing high-dose inhaled nitric oxide as a standard treatment for drug-resistant pneumonia?

Implementing this treatment faces several hurdles. Most hospitals lack the equipment to deliver nitric oxide at high concentrations. The process requires specialized machinery and trained staff, raising concerns about feasibility and accessibility.

4. Why is there a renewed interest in nitric oxide as a treatment for pneumonia?

The rise of antimicrobial resistance (AMR) is driving the renewed interest. As bacteria like Pseudomonas aeruginosa become increasingly resistant to antibiotics, researchers are exploring alternative therapies like nitric oxide to combat these infections.

5. What is Pseudomonas aeruginosa, and why is it a concern in hospital settings?

Pseudomonas aeruginosa is a type of bacteria that causes about one in five hospital-acquired pneumonias. It is concerning because it often resists multiple drugs, making infections difficult to treat.

6. Can you name the key individuals associated with the research on nitric oxide and drug-resistant pneumonia?

Key individuals associated with this research include Lorenzo Berra, Paul H. Edelstein, and Anirban Mukhopadhyay.

Practice Questions (MCQs)

1. Consider the following statements regarding Nitric Oxide (NO): 1. NO acts as a vasodilator, relaxing blood vessels and improving blood flow. 2. NO is produced by the enzyme nitric oxide reductase. 3. NO is only used for treating pulmonary hypertension in newborns. Which of the statements given above is/are correct?

  • A.1 only
  • B.2 only
  • C.1 and 3 only
  • D.1, 2 and 3
Show Answer

Answer: A

Statement 1 is CORRECT: Nitric oxide (NO) indeed acts as a vasodilator, relaxing blood vessels and improving blood flow. This is a well-established property of NO. Statement 2 is INCORRECT: NO is produced by the enzyme nitric oxide synthase (NOS), not nitric oxide reductase. NOS catalyzes the production of NO from L-arginine. Statement 3 is INCORRECT: While NO is used for treating pulmonary hypertension in newborns, its applications extend to other respiratory conditions like ARDS and pneumonia. Current research explores its potential against drug-resistant bacteria.

2. Which of the following statements is NOT correct regarding Pseudomonas aeruginosa? A) It is a bacterium that can cause infections in humans. B) It is becoming increasingly resistant to commonly used antibiotics. C) High-dose inhaled nitric oxide has shown potential in reducing it in animal models. D) It is primarily found in the digestive system of humans.

  • A.It is a bacterium that can cause infections in humans.
  • B.It is becoming increasingly resistant to commonly used antibiotics.
  • C.High-dose inhaled nitric oxide has shown potential in reducing it in animal models.
  • D.It is primarily found in the digestive system of humans.
Show Answer

Answer: D

Options A, B, and C are correct statements about Pseudomonas aeruginosa. It is a bacterium that can cause infections, is becoming increasingly resistant to antibiotics, and has shown potential reduction with high-dose inhaled nitric oxide in animal models. Option D is INCORRECT: Pseudomonas aeruginosa is not primarily found in the digestive system. It is commonly found in the environment, such as in soil and water, and can cause infections in various parts of the body, including the lungs, skin, and blood.

3. Which of the following is the MOST likely reason for the limited use of high-dose inhaled nitric oxide (iNO) in hospitals? A) iNO is only effective against viral infections. B) Most hospitals are not equipped to deliver nitric oxide at high concentrations. C) iNO has been proven to cause severe kidney damage. D) iNO is readily available and inexpensive.

  • A.iNO is only effective against viral infections.
  • B.Most hospitals are not equipped to deliver nitric oxide at high concentrations.
  • C.iNO has been proven to cause severe kidney damage.
  • D.iNO is readily available and inexpensive.
Show Answer

Answer: B

Option B is the correct answer. The news summary explicitly states that most hospitals are not equipped to deliver nitric oxide at high concentrations. The process requires specialized machinery and trained staff, making it a limiting factor in its widespread use. Option A is incorrect because iNO is being explored for bacterial infections, not just viral ones. Option C is incorrect as the news mentions a phase 1 study showed the treatment could be administered without immediate serious complications. Option D is incorrect because the news implies that iNO treatment is not readily available due to equipment and training requirements.

Source Articles

Can a common hospital gas help fight drug-resistant pneumonia? - The Hindu

The Hindu·15 Feb 2026

All you need to know about: pneumonia - The Hindu

The Hindu·15 Feb 2026

UTIs, blood stream infections, typhoid and pneumonia show resistance to commonly used antibiotics: ICMR report - The Hindu

The Hindu·15 Feb 2026

New drug could treat patients hospitalised with COVID-19 pneumonia: Lancet study - The Hindu

The Hindu·15 Feb 2026

Slowing the pace of India’s mucormycosis threat - The Hindu

The Hindu·15 Feb 2026

GKSolverToday's News